Merck Sharpe and Dohme has experienced strong year-on-year growth in the first quarter of 2011.
According to data from the firm's new financial report, revenues for the three months rose by one percent to $11.58 billion (7.02 billion pounds), while double-digit earnings-per-share growth was also recorded.
During the quarter, Merck Sharpe and Dohme saw solid expansions across its pharmaceutical, animal health and consumer care divisions, while individual products including Januvia, Singulair, Remicade and Isentress experienced heightened demand.
Kenneth Frazier, the company's president and chief executive officer, said this growth demonstrates the value of its 2009 merger with Schering-Plough.
"We're making progress in our robust late-stage pipeline and leveraging the benefits of our expanded pharmaceutical and vaccine, animal health and consumer portfolio," he added.
Last month, the firm announced the commencement of a new hexavalent combination vaccine for children, which is being developed in association with Sanofi Pasteur.See all the latest jobs in Pharmaceutical